549 related articles for article (PubMed ID: 24368236)
1. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.
Harrington JM; Schwenke DC; Epstein DR; Bailey DE
Oncol Nurs Forum; 2014 Jan; 41(1):21-9. PubMed ID: 24368236
[TBL] [Abstract][Full Text] [Related]
2. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
3. Exercise preferences among men with prostate cancer receiving androgen-deprivation therapy.
Harrington JM; Schwenke DC; Epstein DR
Oncol Nurs Forum; 2013 Sep; 40(5):E358-67. PubMed ID: 23989028
[TBL] [Abstract][Full Text] [Related]
4. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
Shahani S; Braga-Basaria M; Basaria S
J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
[TBL] [Abstract][Full Text] [Related]
5. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.
Basaria S
J Androl; 2008; 29(5):534-9. PubMed ID: 18567642
[TBL] [Abstract][Full Text] [Related]
7. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients.
Salvador C; Planas J; Agreda F; Placer J; Trilla E; Lopez MA; Morote J
Urol Int; 2013; 90(1):41-4. PubMed ID: 23235105
[TBL] [Abstract][Full Text] [Related]
9. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
[TBL] [Abstract][Full Text] [Related]
10. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
Braga-Basaria M; Dobs AS; Muller DC; Carducci MA; John M; Egan J; Basaria S
J Clin Oncol; 2006 Aug; 24(24):3979-83. PubMed ID: 16921050
[TBL] [Abstract][Full Text] [Related]
11. The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy.
Morote J; Gómez-Caamaño A; Alvarez-Ossorio JL; Pesqueira D; Tabernero A; Gómez Veiga F; Lorente JA; Porras M; Lobato JJ; Ribal MJ; Planas J;
J Urol; 2015 Jun; 193(6):1963-9. PubMed ID: 25541340
[TBL] [Abstract][Full Text] [Related]
12. External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation.
Koontz BF; Lee WR
Arch Esp Urol; 2011 Oct; 64(8):858-64. PubMed ID: 22052767
[TBL] [Abstract][Full Text] [Related]
13. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
[TBL] [Abstract][Full Text] [Related]
14. Metabolic effects of androgen deprivation therapy.
Choi SM; Kam SC
Korean J Urol; 2015 Jan; 56(1):12-8. PubMed ID: 25598932
[TBL] [Abstract][Full Text] [Related]
15. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
Nobes JP; Langley SE; Klopper T; Russell-Jones D; Laing RW
BJU Int; 2012 May; 109(10):1495-502. PubMed ID: 21933330
[TBL] [Abstract][Full Text] [Related]
16. [Androgen deprivation therapy and morbid obesity: do they share cardiovascular risk through metabolic syndrome?].
Cleffi S; Neto AS; Reis LO; Maia P; Fonseca F; Wroclawski ML; Neves M; Pompeo AC; Del Giglio A; Faria EF; Tobias-Machado M
Actas Urol Esp; 2011 May; 35(5):259-65. PubMed ID: 21459486
[TBL] [Abstract][Full Text] [Related]
17. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
18. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
19. Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy.
Hvid T; Winding K; Rinnov A; Dejgaard T; Thomsen C; Iversen P; Brasso K; Mikines KJ; van Hall G; Lindegaard B; Solomon TP; Pedersen BK
Endocr Relat Cancer; 2013 Oct; 20(5):621-32. PubMed ID: 23744766
[TBL] [Abstract][Full Text] [Related]
20. Metabolic and cardiovascular effects of androgen deprivation therapy.
Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
